Press releases

Beactica announces drug discovery agreement with Cubist Pharmaceuticals

Uppsala, Sweden, May 26th, 2009 Beactica AB, the Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Cubist Pharmaceuticals, Inc. (Lexington, MA; NASDAQ: CBST). Under the agreement, Beactica will use its surface plasmon resonance (SPR)-integrated drug... [...]

Beactica welcomes Uppsala University Holding Company as a new shareholder

Uppsala, Sweden, August 15th, 2008 Beactica AB, a fragment-based drug discovery company spun out of Uppsala University, today announced a new investment and the addition of Uppsala University Holding Company to its shareholders. The funding will support Beactica’s growing internal drug discovery pipeline. "We... [...]

Beactica announces drug discovery collaboration with Arrow Therapeutics

Uppsala, Sweden, November 12th, 2007 Beactica AB announced today that it has entered into a drug discovery collaboration agreement with Arrow Therapeutics Ltd (London, UK) whereby Beactica will direct its novel characterisation technology at selected Arrow compounds against a confidential target. "We are... [...]

Beactica expands into new premises

Uppsala, Sweden, November 1st, 2007 Beactica, the specialist drug discovery company spun out of Uppsala University in 2006, announced today that it has moved into new premises at the Uppsala Biomedical Centre. "The move reflects a growing demand for Beactica’s partnership programme from other drug discovery... [...]

Beactica double winner in EU-financed drug discovery projects

Uppsala, Sweden – September 14th, 2007 Beactica, the specialist drug discovery company spun out of Uppsala University in 2006, will partner in two separate projects both of which have been selected for major grants through the 7th EU Framework Programme. In each project Beactica will apply its drug discovery platform... [...]